AU4331601A - Method for detecting and killing epithelial cancer cells - Google Patents
Method for detecting and killing epithelial cancer cells Download PDFInfo
- Publication number
- AU4331601A AU4331601A AU43316/01A AU4331601A AU4331601A AU 4331601 A AU4331601 A AU 4331601A AU 43316/01 A AU43316/01 A AU 43316/01A AU 4331601 A AU4331601 A AU 4331601A AU 4331601 A AU4331601 A AU 4331601A
- Authority
- AU
- Australia
- Prior art keywords
- agent
- cells
- marking
- cancer cells
- mitochondrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000009030 Carcinoma Diseases 0.000 title claims description 24
- 238000000034 method Methods 0.000 title claims description 23
- 230000002147 killing effect Effects 0.000 title claims description 15
- 210000004027 cell Anatomy 0.000 claims description 85
- 239000003550 marker Substances 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 29
- 125000002091 cationic group Chemical group 0.000 claims description 29
- 210000003470 mitochondria Anatomy 0.000 claims description 26
- 230000002438 mitochondrial effect Effects 0.000 claims description 25
- 102100028701 General vesicular transport factor p115 Human genes 0.000 claims description 19
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 210000002919 epithelial cell Anatomy 0.000 claims description 10
- 230000007246 mechanism Effects 0.000 claims description 7
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 210000001700 mitochondrial membrane Anatomy 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- QTWZICCBKBYHDM-UHFFFAOYSA-N leucomethylene blue Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3NC2=C1 QTWZICCBKBYHDM-UHFFFAOYSA-N 0.000 claims 1
- 239000000975 dye Substances 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 229950003937 tolonium Drugs 0.000 description 12
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 12
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 230000005880 cancer cell killing Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000001016 thiazine dye Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 230000025608 mitochondrion localization Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- IOFXEUZPIIUQAG-UHFFFAOYSA-M Tiemonium iodide Chemical compound [I-].C=1C=CSC=1C(O)(C=1C=CC=CC=1)CC[N+]1(C)CCOCC1 IOFXEUZPIIUQAG-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
- SRAVWPVICTXESG-UHFFFAOYSA-N [4-(2,4-diamino-5-methylphenyl)iminocyclohexa-2,5-dien-1-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].C1=C(N)C(C)=CC(N=C2C=CC(C=C2)=[N+](C)C)=C1N SRAVWPVICTXESG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- PGWTYMLATMNCCZ-UHFFFAOYSA-M azure A Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 PGWTYMLATMNCCZ-UHFFFAOYSA-M 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229950008849 furazolium chloride Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- FMPJXUZSXKJUQI-UHFFFAOYSA-N hydron;3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;chloride Chemical compound Cl.O1C([N+](=O)[O-])=CC=C1C1=CSC2=NCCN12 FMPJXUZSXKJUQI-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RNUAEUWXRHCGKX-UHFFFAOYSA-N oxythiamine chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)NC1=O RNUAEUWXRHCGKX-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- XFDQJKDGGOEYPI-UHFFFAOYSA-O peonidin Chemical compound C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 XFDQJKDGGOEYPI-UHFFFAOYSA-O 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- SOUHUMACVWVDME-UHFFFAOYSA-N safranin O Chemical compound [Cl-].C12=CC(N)=CC=C2N=C2C=CC(N)=CC2=[N+]1C1=CC=CC=C1 SOUHUMACVWVDME-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 229960005128 tiemonium iodide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
WO 01/64255 PCT/USO1/06318 -1 METHOD FOR DETECTING AND KILLING EPITHELIAL CANCER CELLS Related Application This application is a continuation-in-part of copending International Application, PCT/US00/05387, filed February 28, 2000, entitled "Method of Detecting and Killing Epitheleal Cancer Cells. Field of the Invention This invention relates to methods for detecting epithelial cancer. In another respect the invention pertains to methods for selectively killing epithelial cancer cells. In a further aspect, the invention concerns methods for detecting epithelial cancer cells in the presence of normal cells and/or for selectively killing such cells, in which the mitochondria of cancer cells retain a mitochondrial marking agent for a time sufficient to permit identification and/or killing such cells.
WO 01/64255 PCT/USO1/06318 -2 Definitions As used herein, the following terms have the indicated meanings: "Cancer" or "cancerous" cells are used in the broad sense, to include invasive cancer cells, cancer-in situ cells and severely dysplastic cells. "Mitochondrial marking agent" means a compound that is selectively taken up by the mitochondria of living cancer cells and is selectively retained in cancer cells for a time sufficient to permit identification and/or killing or incapacitation thereof. "Killing" of cells means either causing cell death, apoptosis or cell changes that render a cell incapable of reproduction and metastasizing. "Adduct" means the reaction product, either covalent or noncovalent, of a mitochondrial marking agent and a cancer chemotherapeutic agent. "Adjuvant" means a mitochondrial marking agent that, in combination with another chemotherapeutic agent, causes improved killing of cancer cells, either WO 01/64255 PCT/USO1/06318 -3 synergistically or by additive effects with the other agent. Background of the Invention In-vivo diagnostic procedures for detecting malignant and premalignant epithelial lesions or carcinomas, employing dye compositions that selectively "color" tissues that are abnormal due to dysplasia, hyperplasia, tumorigenesis and other active surface lesions, are known in the art. These diagnostic methods employ a dye that imparts color to a cancerous substrate, which is then detectable under light at visible wavelengths or a fluorescent dye that imparts color to the substrate, which is then detectable when illuminated by light at wavelengths outside the visible spectrum. For example, procedures employing fluorescein and fluorescein derivatives are disclosed in Chenz, Chinese Journal of Stomatology (27:44-47 (1992)) and Filurin (Stomatologiia (Russian) 72:44-47 (1993)). These procedures involve application of the dye, followed by examination under ultraviolet light to detect the cancerous/precancerous tissue, which is selectively fluorescent. Another prior art procedure involves rinsing the epithelium with toluidine blue, followed by normal visual examination to detect any selectively WO 01/64255 PCT/USO1/06318 -4 stained tissue. Such procedures are disclosed, for example in the patents to Burkett (U.S. 6,086,852), Tucci (U.S. 5,372,801) and Mashberg (U.S. 4,321,251). Use of other thiazine dyes and oxazine dyes in an analogous manner is disclosed in U.S. Patent 5,882,627 to Pomerantz. Heretofore, it was theorized that such dyes selectively "marked" cancerous tissue because the dye was retained in the relatively larger interstitial spaces between the cells of cancerous tissue and would not efficiently penetrate the tighter intracellular junctions of normal tissue or be selectively retained in such relatively smaller spaces. Contrary to the belief that toluidine blue selectively marks cancerous epithelial tissue because it is selectively retained in the relatively larger interstitial spaces between cancer cells, the mechanism of such selective staining of epithelial tissue by cationic dyes, e.g., dyes such as rhodamine, fluoresceins, oxazine and thiazine dyes (including toluidine blue) and other cationic supravital marking agents, is the selective uptake and selective retention of the agent in the mitochondria of cancer cells. This selective mitochondrial uptake and retention is apparently due to the higher electrical potential WO 01/64255 PCT/USO1/06318 -5 (negative charge on the inside of the membrane) of cancerous cells' mitochondria as compared to mitochondria of normal cells. See, e.g., Chen et al., Cancer Cells 1/The Transformed Phenotype, 75-85 (Cold Spring Harbor Laboratory, 1984); Lampidis, et al., Cancer Research 43, 716-720 (1983). In fact, the selective marking of cancer cells by, and retention in the mitochondria of cancer cells of, supravital cationic dyes and other supravital cationic marking agents, are related to one of the very characteristics of cancer cells that appears to be responsible for their rapid cloning growth and metastasizing ability, namely, that the higher electrical potential of the mitochondria of cancer cells is the source of cellular energy and is the driving force for ATP (adenosine triphosphate)production by the cells. Summary of the Invention We have now discovered a method for in-vivo detection of cancerous epithelial cells by selective marking of the mitochondria thereof. In another respect, we have discovered a therapeutic method for selectively killing cancer cells in the presence of normal cells. Our detection methods comprise the steps of WO 01/64255 PCT/USO1/06318 -6 delivering a cationic supravital mitochondrial marking agent to tissue in the locus of a suspect cancerous site on the epithelium (which contains both normal and cancerous cells), thus causing said agent to be taken up and selectively retained in the mitochondria of the cancer cells. The cancerous cells are then detectable by any suitable method, for example, instrumental or visual examination under visible light or under light of selected invisible wavelengths. In a further embodiment, after the marking agent is taken up by the mitochondria, a rinse reagent is applied to the locus of the suspect cancerous site, thus enhancing the rate of release of the agent from the mitochondria of the normal cells and further increasing the selectivity of the diagnostic methods. According to another important embodiment of the invention, we provide a method for selectively killing cancerous epithelial cells comprising the step of contacting cancerous cells in the locus of a suspect cancerous site with a cationic supravital mitochondrial marking agent, to cause cell death or to render the cancer cells substantially incapable of multiplication. The marking agent can be delivered to the cancer cells in a single discrete dose, or continuously, or in repeated discrete doses, with or without employing a rinse reagent WO 01/64255 PCT/USO1/06318 -7 after each dose. In a further embodiment of the invention, we provide a method of improving the selectivity and cancer cell killing ability of cancer chemotherapeutic agents comprising the steps of either (1) forming a reaction product of a cationic supravital agent and a chemotherapeutic agent and delivering the reaction product to cancerous epithelial cells or (2) combining the cationic supravital agent with a cancer chemotherapeutic agent, to improve the selectivity or killing ability of the chemotherapeutic agent, either by additive or synergistic effects, or both. These, other and further embodiments of the invention will be apparent to those skilled in the art and a better understanding of the invention will be obtained from the following examples which are provided to illustrate the invention and not as indications of the scope thereof, which is defined only by the appended claims. In the practice of the invention and in the following working examples, cationic supravital mitochondrial marking agents, include WO 01/64255 PCT/USO1/06318 -8 dyes, including toluidine blue 0, alcian blue, malachite green, phenosafranin, acriflavine, pyronine Y, toluylene blue and brilliant green; and "non-dye" compounds, including peonidin, oxythiamine, tiemonium iodide, elliptinium acetate and furazolium chloride. According to the presently preferred embodiment of the invention, the preferred mitochondrial marking agents are dyes of the oxazine and thiazine class. The thiazine dyes are especially preferred, particularly toluidine blue 0, Azure A, Azure B and ring-substitution and N substitution analogs thereof. In order to be selectively absorbed and retained in cancer cell mitochondria, the marking agent or reaction product of marking agent + chemotherapeutic agent, must have a molecular weight of below about 5,000. Further, because of marked differences in the selective marking and therapeutic activity of various closely related analogs, it appears that the molecular structure of the marking agent significantly affects its ability to selectively mark and/or kill living cancer cells in the presence of normal living cells. These differences in cell marking and killing ability are related to WO 01/64255 PCT/USO1/06318 -9 structural features, e.g., location and type of ring substituents and N-substituents, of the marking agent molecules that implicate one or more or all of the following mechanisms of action: 1. The structure of the marking agent molecule, e.g., position and nature of ring and N-substituents on the cationic molecule, affects the availability of the positive charge and hinders the ability of the marking agent or "stacked" groups of them to be attracted by the negative charges on the mitochondrial membranes or within the mitochondria. 2. The structure of the marking agent molecule permits it to intercalate into or "stack" along the exterior of mitochondrial DNA of cancer cells. 3. The structure of the marking agent molecule permits it or stacked groups of them to bind to specific active sites, e.g., four specific proteins, in the mitochondria, and/or precipitate with cardiolipins at the inner surface of the mitochondrial membrane. 4. The structure of the marking agent affects its reduction potential and its tendency to change to the uncharged "leuco" form.
WO 01/64255 PCT/USO1/06318 -10 5. The structure of the marking agent affects its acidity (pKa), and, in turn, the ability of the cationic marking agent to deprotonate at physiological pH. Thus, the cationic form of the dye can be attracted to the outer surface of the mitochondrial membrane, whereupon the dye cation can lose a proton and concomitantly lose its positive charge, thereby liberating the neutral form of the dye, which may more readily penetrate the nonpolar matrix of the membrane and gain access to the interior of the mitochondrion. The intermolecular interactions of mechanisms 1 dye membrane), 2 (dye-base pair or dye-dye), and 3 (dye protein or dye-lipid) depend on the hydrophobicity lipophilicity of the dye, which can be assessed by various means, one of which is the partition coefficient between aqueous solution and a low-polarity organic solvent, such as 1-octanol (i.e., log P values). Mechanisms 4 and 5 depend on hydrophobicity lipophilicity, due to the effect of differential solvation of reactant and product on reduction potential (oxidized vs. reduced forms) and pK (neutral vs. charged forms). For example, hydrophobicity hampers the solvation of protonated tertiary aliphatic amines (R 3 NH*), thereby decreasing their acidity relative to secondary amines
(R
2
NH
2
')
WO 01/64255 PCT/USO1/06318 -11 According to the presently preferred embodiment of the invention, one employs a cationic supravital marking agent having a log P of from about -1.0 to about 5. The following examples are presented to enable those skilled in the art to understand and practice the invention and to identify the presently preferred embodiment. These examples are for illustrative purposes only are not intended to limit the scope of the invention, which is defined only by the appended claims. Example 1 Uptake and Retention of Mitochondrial Marking Agents in Living Carcinoma Cells Different concentrations of the various cationic marking agents, at 100, 50, 10 and 1 ptg/ml are prepared in RPMI medium complete with 20% fetal calf serum, 1 mM glutamine, hydrocortisone, insulin, transferrin, estradiol, selenium and growth hormone. The carcinoma cells are incubated at 37EC in tissue culture incubators with 5% C02 and 95% relative humidity, for 5 minutes with each agent and concentration there and then rinsed twice using 2 minute incubations with 1% acetic acid. After incubation and rinsing, the cells are harvested, at 30 min., 1 hour, 2 hours, 4 hours and 8 hours. The cells are then extracted with 2-butanol and WO 01/64255 PCT/USO1/06318 -12 analyzed by spectrophotometry for quantitation of the marking agent. The results show that there is a concentration dependence in the rate of accumulation of marking agent in the mitochondria of both carcinoma and normal cells and in the selectivity of release of the marking agent from cancer cells, but this concentration dependence starts to become less pronounced. The saturation concentration for toluidine blue 0 occurs at concentrations of 10pg/ml and above. The saturation concentrations for the other marking agents are similarly determined. The remaining experiments are conducted with a concentration of lOpg/ml for toluidine blue 0 and at the saturation concentrations for the other marking agents so-determined, unless stated otherwise. Example 2 . Mitochondrial Localization of the Agents in Living Cells After incubation and rinsing of various cell lines, using the different cationic marking agents, the mitochondrial localization of the agents is analyzed using confocal high resolution microscopy and phase contrast microscopy. Living cells, are cultivated in complete growth medium with 20% fetal calf serum and growth factors, and WO 01/64255 PCT/USO1/06318 -13 maintained at 37EC. These cells accumulate and retain the marking agents in the mitochondria. When these cells are then maintained in an agent-free medium, carcinoma cells retain the agent for longer than about 1 hour, but normal epithelial cells release the agent within about 15 minutes. In contrast to living cells, dead cells or cells treated with agents that dissipate the mitochondrial membrane potential lose mitochondrial staining and accumulate the agents in the nucleus. Example 3 Release of the Agents from Mitochondria With Dissipation of the Mitochondrial Membrane Potential Known agents that alter the mitochondrial electrical potential are used to pretreat epithelial cancer cells, followed by treatment with the cationic supravital mitochondrial marking agents. These pretreatment agents include azide and cyanide preparations and dinitrophenol. Epithelial cancer cells are also pre-stained with the various dyes and then are post-treated with these known agents. The release of the dyes from the cells or the transfer of the dyes to other subcellular compartments, including the nucleus is analyzed.
WO 01/64255 PCT/US01/06318 -14 The cells pretreated with these agents do not accumulate dyes in the mitochondria and the mitochondria of the pre-stained cells release the dye upon post treatment with these agents. Example 4 Tissue Explants of Squamous Carcinomas Fresh explants of resected epithelial carcinomas are analyzed for marking agent uptake and retention. After resection, the carcinomas are microdissected from surrounding tissue, cut into 3 mm sections and maintained as explant tissue cultures at 37 C. These explants are then incubated with the various agents and then extracted for quantitation of the agent. Oral carcinoma (SqCHN) have rapid uptake and prolonged retention of these agents. The agents start to be released from the cells after about one hour of cultivation in agent-free medium. However, the agents are released faster when the cells are incubated in medium that does not contain growth factors, fetal calf serum and other medium additives. The agents are also released faster when the cells are grown in adverse conditions such as lower temperatures.
WO 01/64255 PCT/USO1/06318 -15 Example 5 Tissue Explants of Normal Epithelial Cells Cells obtained surgically from normal areas of the oral epithelium are cultivated as normal epithelial cultures. These cultures are then incubated with the marking agents for analysis of the agent uptake and retention. Unlike the carcinoma cells, normal epithelial cells quickly release the agents from their mitochondria and from the cell much more quickly. By 10-15 minutes, most of the agent is released from the mitochondria. Example 6 Marking Agent-Chemotherapeutic Agent Adducts In place of the agents of Examples 1-5, the following adducts of cationic mitochondrial marking agents and various known chemotherapeutic agents are employed, with substantially similar results, except that the cancer cell kill rate and selectivity of the chemotherapeutic agent are substantially improved. Marking Agent Chemotherapeutic Agent toluidine blue 0 methotrexate rhodamine 123 nitrogen mustard WO 01/64255 PCT/USO1/06318 -16 Example 7 Adiuvant Compositions The following combinations of known cancer chemotheraputants with mitochondrial marking agents exhibit synergistic or at least additive cancer cell killing effects: Chemotherapeutant Cationic Marking Agent taxol toluidine blue taxotere azure A vincristin alcian blue Selective Therapeutic Effects In the following examples, a toluidine blue drug substance is prepared in accordance with the manufacturing procedures disclose in the U.S. Patent 6,086,852, issued to Burkett on July 11, 2000. Components of the drug substance are then fractionated and separated by semi-preparative HPLC, yielding the analogs identified in the '852 patent as represented by Peaks 5, 6, 7 and 8. The compounds represented by peaks 7 and 8 are toluidine blue regioisomers, having the ring methyl group in the -2 position (peak 8) and the -4 position (peak 7). The compound represented by peak 5 is WO 01/64255 PCT/USO1/06318 -17 the N-demethylated derivative of peak 7 and the compound represented by peak 6 is the N-demethylated derivative of peak 8. Example 8 The compounds represented by peaks 5, 6, 7 and 8, obtained during the fractionation of the toluidine blue 0, are analyzed for their selective toxicity towards living oral carcinoma cells (SqCHN) compared to living normal oral epithelial cells. Separate cultures of squamous carcinoma cells and normal epithelial cells are incubated with the different dye fractions and then washed with dye-free medium. The cells are then re incubated in growth medium and observed over a period of 8 days to determine the extent of cell killing. The compound of peak 6 results in 95% cell death of carcinoma cells, compared to only about 20% killing of normal cells. The compound of peak 8 shows 89% cell death of carcinoma cells whereas it only causes about 20% killing of normal cells. Thus, the selective retention of the compounds of peaks 6 and 8 is selectively toxic towards carcinoma cells. The selective introduction into the mitochondria of cationic dyes leads to disruption of the mitochondrial electrical potential which is the source of cellular WO 01/64255 PCT/USO1/06318 -18 energy and the driving force of ATP (adenosine triphosphate) production of the cells. The ability of carcinoma cells to divide rapidly and to metastasize is dependent upon the availability of this higher energy source. However, effects on electric charge do not appear to be the only mechanism involved, because the compounds represented by peak 5 and peak 7 also are cationic dyes and yet they do not exhibit the same selective toxicity towards carcinomas that Peak 6 and Peak 8 demonstrate. Thus, the compounds of peaks 6 and 8 appear to have other molecular properties that lead to their selective toxicity towards carcinoma cells. Example 9 The therapeutic characteristics of the compounds of peaks 6 and 8 are determined by further in-vitro tests, conducted in the manner of Example 8, using other isolates of carcinoma cells and normal epithelial cells. The testing profile includes other squamous carcinomas of the head and neck, esophagus, lung, cervix and skin, as well as other types of cancers, including adenocarcinomas, lymphomas and sarcomas. In-vivo "delay of tumor growth" and "tumor regression assay" tests using tumor-bearing animals, including head and neck and WO 01/64255 PCT/USO1/06318 -19 lung carcinomas implanted in Balb-C mice, are made to analyze the in-vivo therapeutic benefit of these compounds. These further in vitro and in-vivo tests confirm the selective toxicity of the compounds of peaks 6 and 8 to the wider variety of cancer cell types. Having described the invention in such manner as to enable those skilled in the art to understand and practice it and, having identified the presently preferred embodiments thereof, WE CLAIM:
Claims (10)
1. A diagnostic method for in vivo detection of cancerous epithelial cells by selective marking of the mitochondria thereof, comprising the step of delivering to the epithelium a cationic supravital mitochondrial marking agent.
2. A method for selective killing of epithelial cancer cells comprising the step of delivering to epithelial cancer cells a cationic supravital mitochondrial marking agent.
3. The method of claim 2 in which the agent is the reaction product of a cationic supravital mitochondrial marking agent and a cancer chemotherapeutic drug.
4. The method of claim 2 in which the agent is delivered to epithelial cancer cells in combination with another cancer chemotherapeutic drug that selectively kills cancer cells by a different mechanism than the mechanism by which the agent kills cancer cells.
5. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a molecular structure that does not hinder attraction of the positive charge of the marking agent molecule by the negative charges on the mitochondrial membranes. WO 01/64255 PCT/USO1/06318 -21
6 The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a molecular structure that permits the marking agent to bind to a specific site in the mitochondria.
7. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a structure that will intercalate into or stack along the mitochondrial DNA.
8. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking-agent is selected to provide a molecular structure that affects its reduction potential to permit it to change to the uncharged leuco form prior to, during, or after entry into the mitochondria.
9. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a molecular structure that will deprotonate at physiological pH.
10. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent has a log P of 0-5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/005387 WO2001064110A1 (en) | 2000-02-28 | 2000-02-28 | Method for detecting and killing epithelial cancer cells |
AU2000237154 | 2000-02-28 | ||
PCT/US2001/006318 WO2001064255A1 (en) | 2000-02-28 | 2001-02-27 | Method for detecting and killing epithelial cancer cells |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4331601A true AU4331601A (en) | 2001-09-12 |
AU785489B2 AU785489B2 (en) | 2007-11-15 |
Family
ID=21741108
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2000237154A Abandoned AU2000237154A1 (en) | 2000-02-28 | 2000-02-28 | Method for detecting and killing epithelial cancer cells |
AU43316/01A Ceased AU785489B2 (en) | 2000-02-28 | 2001-02-27 | Method for detecting and killing epithelial cancer cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2000237154A Abandoned AU2000237154A1 (en) | 2000-02-28 | 2000-02-28 | Method for detecting and killing epithelial cancer cells |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1214101A4 (en) |
JP (1) | JP2003525044A (en) |
KR (2) | KR100907122B1 (en) |
CN (1) | CN100544770C (en) |
AU (2) | AU2000237154A1 (en) |
BR (1) | BR0104747A (en) |
CA (1) | CA2370741A1 (en) |
CZ (1) | CZ20013861A3 (en) |
IL (1) | IL146141A0 (en) |
MX (1) | MXPA01010886A (en) |
NO (1) | NO20015242L (en) |
NZ (1) | NZ515202A (en) |
RU (1) | RU2226404C2 (en) |
WO (2) | WO2001064110A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2000237154A1 (en) * | 2000-02-28 | 2001-09-12 | Zila, Inc. | Method for detecting and killing epithelial cancer cells |
EP1294408A4 (en) * | 2000-06-30 | 2005-01-05 | Zila Inc | Rhodamine diagnostic agent and diagnostic methods for detection of epithelial cancer |
AU776256B2 (en) * | 2000-09-26 | 2004-09-02 | Zila Biotechnology, Inc. | Method for early prediction of the onset of invasive cancer |
EP1463838A4 (en) * | 2001-12-14 | 2006-06-07 | Zila Inc | Stain-directed molecular analysis for cancer prognosis and diagnosis |
US7081261B2 (en) * | 2002-05-14 | 2006-07-25 | National Starch And Chemical Investment Holding Corporation | Resistant starch prepared by isoamylase debranching of low amylose starch |
US6929817B2 (en) | 2002-05-14 | 2005-08-16 | National Starch & Chemical Investment Holding Corporation | Slowly digestible starch product |
US6890571B2 (en) | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
AU2002312319A1 (en) * | 2002-06-04 | 2003-12-22 | Zila Biotechnology, Inc. | Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues |
MX2007003777A (en) * | 2004-09-30 | 2007-05-24 | Zila Biotechnology Inc | Light-directed method for detecting and aiding further evaluation of abnormal mucosal tissue. |
WO2006072625A2 (en) | 2005-01-06 | 2006-07-13 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
US20120178674A1 (en) | 2009-07-15 | 2012-07-12 | N.V. Nutricia | Mixture of non-digestible oligosaccharides for stimulating the immune system |
CN105510321A (en) * | 2011-12-29 | 2016-04-20 | 闫文广 | Detection agent composition for epithelial tissue tumor cells and preparing method thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4321251A (en) * | 1979-12-19 | 1982-03-23 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse |
US5194373A (en) * | 1985-06-06 | 1993-03-16 | Thomas Jefferson University | Method of determining endothelial cell coverage of a prosthetic surface |
US4816395A (en) * | 1985-12-19 | 1989-03-28 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
DK0565668T3 (en) * | 1991-10-31 | 2000-01-31 | Zila Inc | Biological dye composition, method of preparation thereof and for use in epithelial cancer signaling |
KR100342342B1 (en) * | 1996-01-16 | 2002-08-22 | 자일러, 인코포레이티드 | Methods and compositions for in-vivo detection of oral cancers and precancerous conditions |
US6086852A (en) * | 1997-11-13 | 2000-07-11 | Zila, Inc. | In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
CN1346282A (en) * | 1998-12-23 | 2002-04-24 | G.D.西尔公司 | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia |
AU2000237154A1 (en) * | 2000-02-28 | 2001-09-12 | Zila, Inc. | Method for detecting and killing epithelial cancer cells |
AU785490B2 (en) * | 2000-07-20 | 2007-11-15 | Zila Biotechnology, Inc. | Improved diagnostic method for detecting dysplastic epithelial tissue |
AU776256B2 (en) * | 2000-09-26 | 2004-09-02 | Zila Biotechnology, Inc. | Method for early prediction of the onset of invasive cancer |
-
2000
- 2000-02-28 AU AU2000237154A patent/AU2000237154A1/en not_active Abandoned
- 2000-02-28 WO PCT/US2000/005387 patent/WO2001064110A1/en active Application Filing
-
2001
- 2001-02-27 RU RU2001132076/15A patent/RU2226404C2/en not_active IP Right Cessation
- 2001-02-27 AU AU43316/01A patent/AU785489B2/en not_active Ceased
- 2001-02-27 EP EP01916271A patent/EP1214101A4/en not_active Ceased
- 2001-02-27 MX MXPA01010886A patent/MXPA01010886A/en active IP Right Grant
- 2001-02-27 IL IL14614101A patent/IL146141A0/en unknown
- 2001-02-27 CZ CZ20013861A patent/CZ20013861A3/en unknown
- 2001-02-27 NZ NZ515202A patent/NZ515202A/en unknown
- 2001-02-27 KR KR1020017013731A patent/KR100907122B1/en not_active IP Right Cessation
- 2001-02-27 CA CA002370741A patent/CA2370741A1/en not_active Abandoned
- 2001-02-27 WO PCT/US2001/006318 patent/WO2001064255A1/en active Application Filing
- 2001-02-27 BR BR0104747-7A patent/BR0104747A/en not_active Application Discontinuation
- 2001-02-27 JP JP2001563152A patent/JP2003525044A/en active Pending
- 2001-02-27 CN CNB018006604A patent/CN100544770C/en not_active Expired - Fee Related
- 2001-02-27 KR KR1020087020377A patent/KR20080080681A/en not_active Application Discontinuation
- 2001-10-26 NO NO20015242A patent/NO20015242L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL146141A0 (en) | 2002-07-25 |
KR20080080681A (en) | 2008-09-04 |
AU785489B2 (en) | 2007-11-15 |
RU2226404C2 (en) | 2004-04-10 |
CA2370741A1 (en) | 2001-09-07 |
NO20015242D0 (en) | 2001-10-26 |
EP1214101A4 (en) | 2005-04-13 |
JP2003525044A (en) | 2003-08-26 |
NZ515202A (en) | 2003-05-30 |
CN1365288A (en) | 2002-08-21 |
KR20020000222A (en) | 2002-01-05 |
WO2001064255A1 (en) | 2001-09-07 |
EP1214101A1 (en) | 2002-06-19 |
WO2001064110A1 (en) | 2001-09-07 |
AU2000237154A1 (en) | 2001-09-12 |
CZ20013861A3 (en) | 2002-08-14 |
MXPA01010886A (en) | 2002-05-06 |
NO20015242L (en) | 2001-11-29 |
KR100907122B1 (en) | 2009-07-09 |
CN100544770C (en) | 2009-09-30 |
BR0104747A (en) | 2002-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leonidova et al. | Photo-induced uncaging of a specific Re (I) organometallic complex in living cells | |
AU785489B2 (en) | Method for detecting and killing epithelial cancer cells | |
US6756063B2 (en) | Methods and compositions for the treatment of human and animal cancers | |
Zhuang et al. | Mitochondrion-targeted selenium nanoparticles enhance reactive oxygen species-mediated cell death | |
WO2011116142A1 (en) | Method of using near infrared fluorescent dyes for imaging and targeting cancers | |
HU228208B1 (en) | Palladium-substituted bacteriochlorophyll derivatives and use thereof | |
Chubarov et al. | Design of protein homocystamides with enhanced tumor uptake properties for 19F magnetic resonance imaging | |
Chan et al. | Photodynamic activity of a glucoconjugated silicon (IV) phthalocyanine on human colon adenocarcinoma | |
US6649144B1 (en) | Method for detecting and killing epithelial cancer cells | |
US20030017158A1 (en) | Method for detecting and killing epithelial cancer cells | |
Vuong et al. | Hypericin incorporation and localization in fixed HeLa cells for various conditions of fixation and incubation | |
Nazarova et al. | 13, 15-N-cycloimide derivatives of chlorin p6 with isonicotinyl substituent are photosensitizers targeted to lysosomes | |
US20230149567A1 (en) | Mechanical opening of lipid bilayers by molecular nanomachines | |
US20140227188A1 (en) | Compositions and Methods for Using Cathepsin E Cleavable Substrates | |
RU2713151C1 (en) | Conjugate of a fluorescent dye with a peptide substance which contains a psma-binding ligand based on a urea derivative for visualizing cells expressing psma, a method for production thereof and use thereof | |
CA2120002C (en) | Cytodiagnostic method using alstonine as a selective marker, and diagnostic kit containing said marker | |
BRPI0612367A2 (en) | cell or tissue labeling solution, kit, method of ex vivo cell or tissue labeling, use of an in vitro solution and method of diagnosing cancer or dysplasia | |
CN113358615A (en) | Application of melane and fluorescein sodium double staining method in living cell imaging | |
Winkelman et al. | Staining with tetraphenylporphinesulfonate in vivo | |
Varmazyad et al. | N-alkyl triphenylvinylpyridinium conjugated dihydroartemisinin perturbs mitochondrial functions resulting in enhanced cancer versus normal cell toxicity | |
Miyagi et al. | Crystal violet combined with Merocyanine 540 for the ex vivo purging of hematopoietic stem cell grafts | |
US20230149451A1 (en) | Pharmaceutical composition comprising oxidizable biphenol and manganese porphyrin, and method of using the same | |
Sharma et al. | Photodynamic action of merocyanine 540 on carcinoma of cervix cells. | |
Schmid et al. | Differential uptake of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea and doxorubicin by Lewis lung carcinoma and Ridgway osteogenic sarcoma | |
Fioretti et al. | Monitoring of hematoporphyrin injected in humans and clinical prospects of its use in gynecologic oncology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: ZILA BIOTECHNOLOGY, INC. Free format text: THE FORMER OWNER WAS: ZILA, INC. |